Roche on Monday said it will buy Spark Therapeutics in a transaction valued at $4.3 billion as the Swiss drugmaker builds its hemophilia portfolio and seeks to keep pace in gene therapy with rivals like Novartis.

https://ift.tt/2SmaSY5 support@endlesssupplies.biz (Endless Supplies .Biz) February 25, 2019 at 01:02AM
No comments:
Post a Comment